Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Haematological Malignancy: early-phase trial registry

2 of 2 indexed Haematological Malignancy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Haematological Malignancy: 2 US clinical trials tracked, 2 recruiting.

Haematological Malignancy is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is The University of Queensland, running 1 of these trials.

Enrollment posture brief

Registry condition haematological-malignancy

OPEN 2 | RECR 100% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Haematological Malignanc (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Haematological Malignancy

Haematological Malignancy lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Haematological Malignancy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Haematological Malignancy is recruiting above its size-band peers.

    2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on Haematological Malignancy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

genotype-directed dosing with dosing software based on therapeutic drug monitoring Other
1 trials
CCS1477 Drug
1 trials
Pomalidomide Drug
1 trials
Dexamethasone Drug
1 trials
Azacitidine Drug
1 trials
Venetoclax Drug
1 trials

US sites by state

Facility locations filed on Haematological Malignancy trials. A trial with sites in several states counts in each.

Washington 1 trials
Pennsylvania 1 trials
Nebraska 1 trials
Maryland 1 trials
Indiana 1 trials
Georgia 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Haematological Malignancy page

2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Haematological Malignancy condition card totals 2 registered trials; most-linked intervention genotype-directed dosing with dosing software based on therapeutic drug monitoring; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.